Morgan Stanley’s Artiva Biotherapeutics ARTV Stock Holding History

Morgan Stanley’s Portfolio ARTV Stock Details ARTV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.5K	Sell	2,212 -14,165	-86%	-$129K	﹤0.01%	6783
2026 Q1	$105K	Sell	16,377 -10,695	-40%	-$52.9K	﹤0.01%	6132
2025 Q4	$116K	Sell	27,072 -15,757	-37%	-$59.5K	﹤0.01%	6127
2025 Q3	$123K	Sell	42,829 -3,418	-7%	-$9.15K	﹤0.01%	6064
2025 Q2	$69.8K	Buy	46,247 +18,427	+66%	+$38.7K	﹤0.01%	6251
2025 Q1	$83.5K	Sell	27,820 -9,467	-25%	-$51.1K	﹤0.01%	6097
2024 Q4	$376K	Sell	37,287 -2,666	-7%	-$32K	﹤0.01%	5545
2024 Q3	$617K	Buy	+39,953	New	+$463K	﹤0.01%	5304

Other funds holding ARTV

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Morgan Stanley's ARTV Position: Q2 2026 in Review

Morgan Stanley reduced its Artiva Biotherapeutics (ARTV) stake by 86% in Q2 2026, selling an estimated $129K and leaving 2,212 shares worth $21.5K. The position accounts for ﹤0.01% of the portfolio, ranked #6783.

Morgan Stanley first reported a position in ARTV in Q3 2024 and has held it in 8 quarters since. The position peaked at $617K in Q3 2024. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

Morgan Stanley held 2,212 shares of Artiva Biotherapeutics worth $21.5K as of Q2 2026.
Morgan Stanley sold 14,165 Artiva Biotherapeutics shares in Q2 2026, an estimated $129K.
Artiva Biotherapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6783 holding.
Morgan Stanley first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 8 quarters since.
Morgan Stanley's Artiva Biotherapeutics position peaked at $617K in Q3 2024.
72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.